MDA-MB-453 Xenograft Model Service for Breast Cancer

The MDA-MB-453 xenograft model delivers a highly specialized in vivo translational platform specifically engineered to evaluate candidate therapies targeting AR-positive, HER2-driven molecular apocrine breast cancers. Alfa Cytology provides a comprehensive, end-to-end MDA-MB-453 xenograft model service, integrating fully authenticated cellular assets with standardized procedural protocols to accelerate preclinical oncology drug discovery timelines.

Overview of MDA-MB-453 Xenograft Model for Breast Cancer

The MDA-MB-453 cell line is a molecularly unique human mammary carcinoma model valued in preclinical oncology for representing the distinct molecular apocrine or HER2-enriched subtype of breast cancer. Originally isolated from the pleural effusion of a patient with advanced breast adenocarcinoma, this model is characteristically defined by the absence of ER and PR expression, alongside a robust over-expression and amplification of the HER2 receptor. Crucially, MDA-MB-453 exhibits a significant genetic hallmark: high expression of AR coupled with oncogenic mutations in the PIK3CA gene (specifically the H1047R hot-spot mutation). This unique convergence of AR signaling, HER2 activation, and PI3K pathway hyperactivation makes the MDA-MB-453 model an indispensable preclinical test matrix for validating novel AR antagonists, HER2-targeted agents, ADCs, PI3K inhibitors, and synergistic combination therapies designed to bypass targeted resistance mechanisms.

When established in vivo as a xenograft in immunodeficient mice, MDA-MB-453 cells form solid, poorly differentiated tumors that faithfully preserve the complex genomic signatures, androgen responsiveness, and receptor profiles seen in clinical patients.

Cell Line Information: MDA-MB-453

The MDA-MB-453 cell line maintains a stable epithelial-like morphology in vitro and reliably preserves its distinct HER2 amplification, AR expression, and PIK3CA mutational hallmarks upon in vivo transplantation.

Our Services

Alfa Cytology provides a fully integrated, turnkey solution for the MDA-MB-453 Xenograft Model Service. Our dedication to quality begins with rigorous cell line authentication and mycoplasma testing. We manage every critical step of the preclinical journey—from standardized cell preparation, orthotopic or subcutaneous inoculation, in-life monitoring, to comprehensive endpoint analyses including IHC for AR and HER2 expression and PK/PD profiling. Leveraging our expertise in AR-positive, HER2-driven molecular apocrine breast cancer models, we deliver robust data packages tailored to accelerate your drug discovery programs.

Workflow of MDA-MB-453 Xenograft Model Construction

Alfa Cytology executes a standardized and strictly regulated workflow to build and validate the MDA-MB-453 xenograft model:

• Cell Culture & Quality Control: MDA-MB-453 cells are cultivated in cell-bank-certified growth media under optimized parameters. Quality control verification involves mandatory STR profiling and mycoplasma clearance checks to guarantee phenotypic identity and purity before inoculation.
• Host Selection & Acclimatization: Standardized immunocompromised mice are selected based on specific study designs and acclimated to controlled facility parameters to ensure baseline physiological stability.
• Precision Inoculation: A calibrated suspension of high-viability MDA-MB-453 cells is prepared and blended with a verified biological matrix carrier to enhance cell engraftment and overcome fastidious growth barriers. The mixture is precisely injected in vivo via subcutaneous or orthotopic routes.
• Longitudinal Growth Tracking: Following model establishment, tumor growth is tracked systematically using high-precision digital calipers under continuous health monitoring. Animal weights and general welfare behavior are routinely recorded to establish dependable growth kinetics.
• Stratification & Dosing: Once the tumors reach a predetermined, statistically optimal volume range, animals are randomized into therapeutic cohorts to balance group parameters perfectly before dosing protocols begin.

Fig 1. MDA-MB-453 Xenograft Model Construction Workflow

Case Study - MDA-MB-453 Xenograft Model Development

In a recent preclinical trial conducted at Alfa Cytology, the MDA-MB-453 xenograft model was successfully utilized to evaluate the efficacy of a novel therapeutic combination combining a next-generation AR antagonist with a HER2-targeted antibody-drug conjugate. Under optimized modeling conditions and standardized matrix-assisted inoculation protocols, our technical team achieved highly reproducible tumor engraftment and exceptionally uniform growth curves across all experimental arms, allowing for an unobstructed and definitive assessment of therapeutic efficacy.

Our Advantages

Choosing the right partner for your AR-positive, HER2-driven molecular apocrine breast cancer research is critical for generating high-quality, reproducible data. Alfa Cytology stands out by offering specialized expertise and high-standard preclinical services:

• Model Authenticity: Fully verified human tumor cell lines with stable, traceable genetic hallmarks.
• Technical Consistency: Optimized inoculation and microenvironmental protocols ensuring uniform tumor growth and minimizing variance.
• Multi-Parametric Endpoints: Capacity for advanced readouts, including digital tumor kinetics, AR/HER2 pathway profiling, and PK/PD tissue processing.
• Regulatory Compliance: Studies executed by a specialized team adhering strictly to international preclinical research standards.

Contact Us

Are you looking to advance your therapeutic pipeline against AR-positive, HER2-driven molecular apocrine breast cancer using the robust MDA-MB-453 xenograft platform? The expert scientific team at Alfa Cytology is ready to build a customized study design that fulfills your strategic research goals. Please contact us today to speak directly with an oncology specialist and request a project-specific consultation and quotation.

For research use only. Not intended for any clinical use.